Trastuzumab in Elderly Patients — and Those With Other Illnesses

No. Trastuzumab is dosed by body weight, and age alone does not change that calculation. What age may change is how often your heart is checked during treatment, because older patients often have less cardiac reserve to absorb any reduction in pumping efficiency. Your oncologist follows NCCN dosing regardless of age but may increase the frequency of echocardiograms based on your individual cardiac history.

Possibly, but with more monitoring. Pre-existing heart weakness does not automatically exclude you. Your oncologist and a cardiologist will assess your current heart function before treatment starts. If your pumping efficiency is significantly reduced, treatment may be deferred until your cardiac condition is better managed rather than cancelled outright. The goal is to bring your heart to a point where treatment can proceed safely.

NCCN guidance recommends checking heart function before starting and at regular intervals during treatment. The exact frequency depends on your individual cardiac history. If you had heart problems before starting, or if your function drops during treatment, checks will happen more often. You do not need to wait for a scheduled scan to report new symptoms — breathlessness, ankle swelling or palpitations should be reported the same day.

No. Trastuzumab is a monoclonal antibody that is not cleared by the kidneys, so kidney disease does not require a dose adjustment. That said, tell your oncology team about your kidney condition because it shapes how they monitor your overall health during treatment and which other medications can be safely used alongside trastuzumab.

Report the same day if you notice new breathlessness — including when walking slowly or lying flat — swelling in your ankles or legs, a rapid, irregular or pounding heartbeat, or unusual tiredness that feels different from ordinary treatment fatigue. These can be the first signs that your heart is being affected. Do not wait to see whether they settle on their own.

The heart effects of trastuzumab are generally reversible, which is an important difference from some chemotherapy drugs that can cause lasting heart muscle damage. If your pumping function drops during treatment, the usual response is to pause trastuzumab and support the heart. According to ASCO and ESC cardio-oncology guidance, most patients who experience this effect recover enough to resume treatment. Permanent impairment is uncommon but possible, which is why monitoring continues throughout.

Hypertension does not stop you from having trastuzumab, but it needs to be well controlled before and throughout treatment. Uncontrolled high blood pressure adds strain to the heart at the same time trastuzumab is being monitored for its own cardiac effects. Tell your oncology team which blood pressure medications you take so they can confirm there are no interactions with your overall treatment plan.

This is a question your oncologist and a cardiologist will answer together. Some chemotherapy drugs — particularly anthracyclines — carry their own cardiac risk, and the combined effect needs to be weighed carefully against the benefit of both treatments. ASCO guidance addresses this combination specifically. The answer is not always no, but the decision needs to be made with full information about your heart history, your current function, and which chemotherapy is being considered.